A Phase I/IIa Rollover Study of the Whole-Cell Vaccine SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Ipilimumab or Pembrolizumab

Trial Profile

A Phase I/IIa Rollover Study of the Whole-Cell Vaccine SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Ipilimumab or Pembrolizumab

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Mar 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Pembrolizumab (Primary) ; SV-BR-1-GM breast cancer vaccine BriaCell Therapeutics (Primary) ; Cyclophosphamide; Interferon alpha-2b
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Proof of concept
  • Sponsors BriaCell Therapeutics Corp
  • Most Recent Events

    • 16 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 18 Jan 2018 Planned initiation date changed from 15 Dec 2017 to 31 Jan 2018.
    • 08 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 15 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top